Evidence map›Paper›PMID 36518504›Full record

ArticleFrontiers in plant science2022

Chitin-induced systemic disease resistance in rice requires both OsCERK1 and OsCEBiP and is mediated

Momoko Takagi, Kei Hotamori, Keigo Naito, Sumire Matsukawa, Mayumi Egusa, Yoko Nishizawa, Yuri Kanno, Mitsunori Seo, Shinsuke Ifuku, Akira Mine and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in plant science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Momoko TakagiFaculty of Agriculture, Tottori University, Tottori, Japan.
Kei HotamoriFaculty of Agriculture, Tottori University, Tottori, Japan.
Keigo NaitoDepartment of Agricultural Science, Graduate School of Sustainability Science, Tottori University, Tottori, Japan.
Sumire MatsukawaDepartment of Agricultural Science, Graduate School of Sustainability Science, Tottori University, Tottori, Japan.
Mayumi EgusaFaculty of Agriculture, Tottori University, Tottori, Japan.
Yoko NishizawaInstitute of Agrobiological Sciences, National Agriculture and Food Research Organization, Tsukuba, Japan.
Yuri KannoRIKEN Center for Sustainable Resource Science, Yokohama, Japan.
Mitsunori SeoRIKEN Center for Sustainable Resource Science, Yokohama, Japan.
Shinsuke IfukuGraduate School of Engineering, Tottori University, Tottori, Japan.
Akira MineGraduate School of Agriculture, Kyoto University, Kyoto, Japan.
Hironori KaminakaFaculty of Agriculture, Tottori University, Tottori, Japan.
Tottori University · JPRIKEN Center for Sustainable Resource Science · JPJapan Science and Technology Agency · JPNational Agriculture and Food Research Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chitin is a well-known elicitor of disease resistance and its recognition by plants is crucial to perceive fungal infections. Chitin can induce both a local immune response and a systemic disease resistance when provided as a supplement in soils. Unlike local immune responses, it is poorly explored how chitin-induced systemic disease resistance is developed. In this study, we report the systemic induction of disease resistance against the fungal pathogen

Indexed as

Bipolaris oryzaeCEBiPcell-wall biogenesisCERK1chitindisease resistancerice (Oryza sativa)systemic signalling

Identifiers

PMID36518504
PMCPMC9742455
OpenAlexW4310256140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.